Bard clarification
This article was originally published in The Gray Sheet
Executive Summary
Firm's anti-infection endotracheal tube is coated with a new formulation of silver hydrogel anti-microbial technology internally developed by Bard and specifically formulated to address ventilator-associated pneumonia. The device does not use BactiGuard technology, as previously reported (1"The Gray Sheet" April 21, 2003, p. 21)...
You may also be interested in...
Bard Surgery, Vascular Offerings Lead Q1 Growth; Margins Help Boost R&D
FDA has indicated that Bard's anti-infection endotracheal tube will be regulated as a device/drug combination product, the firm says
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.